SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...


Athersys is a clinical-stage biotechnology company that has established a pipeline of therapeutic product development programs in multiple disease indications. The company’s product portfolio consists of MultiStem, a non-embryonic stem cell-based approach for treating disease indications in the areas of inflammatory and immune, neurological and cardiovascular disease.